Startups channel feed – Endpoints News

Startups channel feed

With $500M-plus, a buyout and two new billion-dollar pacts, upstart Vir is ready to roll on infectious diseases

8 years ago

Pfizer, NEA back Cydan II's plans to launch a fresh slate of biotech startups focused on rare genetic diseases

8 years ago

Armed with $42.5M, Gemini embraces the Goldilocks strategy in bringing precision med to AMD

8 years ago

Four years after it imploded at Sanofi, John Hood is resurrecting the myelofibrosis drug fedratinib

8 years ago

Bain, RA back InflaRx’s $55M round after early study produces promising results

8 years ago

Medicxi kickstarts a new cancer drug developer with $19M launch round

8 years ago

Facebook billionaires Peter Thiel and Sean Parker backing a stealth immunotherapy biotech — report

8 years ago

Armed with a $47M round, Gates-backed Visterra aims at a PhIIb flu drug study

8 years ago

Backed by Big Pharma VCs, Palleon ramps up a new approach to immuno-oncology with a $48M startup round

8 years ago

Top scientists and BD execs craft Cullinan, a $150 million R&D portfolio shop focused on cancer

8 years ago

Genzyme vet David Meeker takes helm at stealthy KSQ with $76M and a new map for drug discovery

8 years ago

GSK spinout NeRRe splits the pipeline, creates its own spinout

8 years ago

Two young scientists bag $20M to perfect their CRISPR attack on disease-causing bacteria at upstart Eligo

8 years ago

Pfizer spins off drug orphans into a PhIII-ready startup backed by Bain to the tune of $103M

8 years ago

OrbiMed, RA Capital back a $26M raise for Realm’s two mid-stage drugs

8 years ago

With help from J&J, upstart Provention lands rights to two mid-stage IBD drugs and shoots for PhII

8 years ago

Chris Garabedian's Xontogeny shepherds its first biotech through a $10M startup round

8 years ago

Tech maven Travis May takes the helm of Roivant's data mining startup

8 years ago

From big biopharma to biotech CEO, John Houston’s R&D journey highlights a fast-changing world

8 years ago

Atlas ramps up a new biotech player focused on neurology, with a $30M round to fund the work

8 years ago

Harvard biotech wiz Greg Verdine grabs a $55M A round to build a groundbreaking biotech

8 years ago

Cut loose from Biogen buyout option, Rodin preps for an early-stage shot at Alzheimer’s

8 years ago

Searching for a few great drugs, BridgeBio bags $135M to back a fresh slate of R&D bets

8 years ago

ProQR spins out a new RNA biotech focused on CNS diseases

8 years ago

First page Previous page 67 68 697071 72 73 Next page Last page